Inovio Pharmaceuticals INO makes DNA medicines to potentially treat and prevent diseases associated with human papillomavirus (HPV), cancer and infectious ailments, using its proprietary optimized ...

The company reiterated its plan to submit the BLA for INO-3107 under the FDA's rolling submission process in mid-2025, aiming for FDA acceptance of the filing by year-end and a potential PDUFA date in ...

We have seen 50 institutional investors add shares of $INO stock to their portfolio, and 37 decrease their positions in their most recent quarter.

Shares of Inovio Pharmaceuticals INO jumped 20.6% on Wednesday after the FDA agreed to the company’s rolling submission timeline for the biologics license application (BLA) seeking approval for ...